Vericiguat got for its win in reducing heart failure hospitalization or cardiovascular death in the pivotal in heart failure with reduced ejection fraction, despite only for now. (Endpoints News)
Aside from ISCHEMIA, the other major late-breaking clinical trials, and (who can forget) the , there was much more happening at the American Heart Association (AHA) meeting in Philadelphia:
- who could tolerate staying on neurohormonal blockade drugs had better survival and quality of life in a registry study (JAMA Cardiology)
- didn't hurt diastolic function in the phase II COSMIC-HF trial in patients with heart failure and systolic dysfunction, Amgen, Cytokinetics, and Servier announced
- Twice-yearly inclisiran in heterozygous familial hypercholesterolemia in the phase III ORION-9 trial, akin to the ORION-10 results in the secondary prevention setting, The Medicines Company announced
- Looking just at emergency department treatment in a post-hoc analysis of the SPECTRUM study, converted atrial fibrillation to sinus rhythm in 70.2% of all treated episodes, Correvio announced
- Bone marrow-derived stem cells looked safe and showed potential to with the congenital heart defect hypoplastic left heart syndrome in a pilot study
- guided by invasive coronary angiography led to better resolution of symptoms and quality of life (JACC: Cardiovascular Interventions)
- Anatomic testing provided better prognostication in in younger patients, whereas functional testing was better for seniors in the PROMISE trial (JAMA Cardiology)
Amid a major campaign from the AHA against youth vaping, Apple said it would from its App Store. (Cardiovascular Business)
Apple also launched its for a longitudinal look at how heart health factors are linked to physical activity. (MobiHealthNews)
-- not just those thought to be candidates for thrombectomy -- improved large vessel occlusion detection, sped intervention, and showed a trend for improved outcomes. (Stroke)
are still rolling into the FDA from Watchman and other heart devices despite the agency saying it had stopped one such controversial program, the Minneapolis Star Tribune reported.
A multidisciplinary expert panel released recommendations for in the Annals of Emergency Medicine.
The , a transcatheter device to cinch scarred left ventricle tissue together akin to surgical remodeling for heart failure got breakthrough device status from the FDA, BioVentrix announced.
Edwards Lifesciences is recalling its due to potential for embolization from damage to the inner line in manufacturing. (MassDevice)
A novel pacing strategy to increased cardiac blood flow in a rat model of heart failure. (Journal of Physiology)
The American Medical Association and AHA announced a survey showing that about half of healthcare providers haven't been since school, which the groups said emphasizes a need for their new online training course.